NeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors
| NBSEDelisted Stock | USD 1.62 0.17 9.50% |
About 62% of NeuBase Therapeutics' investor base is looking to short. The analysis of current outlook of investing in NeuBase Therapeutics suggests that many traders are alarmed regarding NeuBase Therapeutics' prospects. The current market sentiment, together with NeuBase Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use NeuBase Therapeutics stock news signals to limit their universe of possible portfolio assets.
NeuBase |
Data show that Stealth Editors achieve ex vivo gene editing using simple synthetic reagents to harness the cells own high-fidelity editing machineryData show that Stealth Editors do not elicit a cell-based immunity and promise a non-immunogenic in vivo solution Data show that Stealth Editors can be encapsulated via established lipid nanoparticle technologies promising a non-immunogenic delivery solution and a de-risked pathway to address therapeutic targets in the liverData featured in an or
Read at finance.yahoo.com
 |
NeuBase Therapeutics Fundamental Analysis
We analyze NeuBase Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeuBase Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeuBase Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
NeuBase Therapeutics is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
NeuBase Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NeuBase Therapeutics stock to make a market-neutral strategy. Peer analysis of NeuBase Therapeutics could also be used in its relative valuation, which is a method of valuing NeuBase Therapeutics by comparing valuation metrics with similar companies.
Peers
NeuBase Therapeutics Related Equities
| ZVSA | ZyVersa Therapeutics | 5.66 | ||||
| IMMX | Immix Biopharma | 5.48 | ||||
| PHGE | Biomx | 1.56 | ||||
| CGEM | Cullinan Oncology | 0.24 | ||||
| IVA | Inventiva | 2.32 | ||||
| CNSP | Cns Pharmaceuticals | 2.36 | ||||
| NAMS | NewAmsterdam Pharma | 2.37 | ||||
| SONN | Sonnet Biotherapeutics | 3.03 | ||||
| CMPX | Compass Therapeutics | 6.18 | ||||
| GLUE | Monte Rosa | 9.85 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in NeuBase Stock
If you are still planning to invest in NeuBase Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuBase Therapeutics' history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |